Zhang Junxian, Zhang Haiyan, Wang Jie, Sun Wenna, Liang Yan, Yang Yourong, Ma Qingwei, Wu Xueqiong
Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Institute of Tuberculosis Research, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing, China.
Bioyong Technologies Inc., Beijing, China.
Microbiol Spectr. 2025 Jul;13(7):e0048325. doi: 10.1128/spectrum.00483-25. Epub 2025 May 30.
Rifampin (RIF) resistance in () is primarily caused by mutations in the gene. Rapid and accurate detection of RIF resistance is critical for effective tuberculosis (TB) control. Nucleotide matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is an emerging technology used to detect RIF resistance-associated mutations in 210 . clinical isolates, including 107 RIF-sensitive and 103 RIF-resistant strains, as determined by phenotypic drug susceptibility testing (DST). DNA sequencing was used as the reference method to validate nucleotide MALDI-TOF MS results. Nucleotide MALDI-TOF MS demonstrated a sensitivity of 93.2%, specificity of 98.1%, and an overall accuracy of 95.7% compared to phenotypic DST. The Kappa value between nucleotide MALDI-TOF MS and phenotypic DST was 0.91, indicating excellent agreement. DNA sequencing confirmed that nucleotide MALDI-TOF MS successfully identified RIF resistance-associated mutations, particularly in codons 450, 445, and 435 of the gene. Among the 61 isolates analyzed by DNA sequencing, nucleotide MALDI-TOF MS and sequencing results were consistent for 52 of 56 RIF-resistant strains and all five RIF-sensitive strains, with an overall concordance of 93.4%. Importantly, nucleotide MALDI-TOF MS accurately detected heteroresistance in eight isolates (14.3%), confirmed by sequencing. These results support that nucleotide MALDI-TOF MS is a rapid, accurate, and reliable method for detecting mutations associated with RIF resistance in . Its high concordance with DNA sequencing, excellent diagnostic performance, and ability to identify heteroresistance highlight its potential as a valuable tool for early TB diagnostics and improve the precision of chemotherapy regimen development.IMPORTANCEThe emergence of multidrug-resistant tuberculosis (MDR-TB) and rifampin-resistant tuberculosis (RR-TB) poses a significant challenge to global tuberculosis (TB) control efforts. Rifampin (RIF) resistance is a critical marker for MDR-TB, which requires more complex, prolonged, and costly treatment regimens. Early and accurate detection of RIF resistance is crucial for effective TB control. This study evaluates the performance of nucleotide MALDI-TOF MS, an innovative technology, for detecting RIF resistance-associated mutations in the rpoB gene. The method demonstrates high sensitivity (93.2%) and specificity (98.1%), with the added advantage of identifying heteroresistance, capabilities that are lacking in conventional methods. These capabilities are crucial for early diagnosis, guiding personalized treatment regimens, and curbing the transmission of drug-resistant TB. The findings demonstrate that nucleotide MALDI-TOF MS provides a rapid, high-throughput, and cost-effective alternative for detecting rpoB gene mutations associated with RIF resistance.
结核分枝杆菌对利福平(RIF)耐药主要由rpoB基因突变引起。快速准确地检测利福平耐药对于有效控制结核病(TB)至关重要。核苷酸基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF MS)是一项新兴技术,用于检测210株临床分离株中与利福平耐药相关的rpoB基因突变,这些分离株经表型药物敏感性试验(DST)确定,包括107株利福平敏感株和103株利福平耐药株。采用DNA测序作为参考方法来验证核苷酸MALDI-TOF MS的结果。与表型DST相比,核苷酸MALDI-TOF MS的灵敏度为93.2%,特异性为98.1%,总体准确率为95.7%。核苷酸MALDI-TOF MS与表型DST之间的Kappa值为0.91,表明一致性良好。DNA测序证实,核苷酸MALDI-TOF MS成功鉴定出与利福平耐药相关的突变,特别是在rpoB基因的450、445和435密码子处。在通过DNA测序分析的61株分离株中,56株利福平耐药株中的52株以及所有5株利福平敏感株的核苷酸MALDI-TOF MS和测序结果一致,总体一致性为93.4%。重要的是,核苷酸MALDI-TOF MS准确检测出8株分离株(14.3%)中的异质性耐药,测序结果证实了这一点。这些结果支持核苷酸MALDI-TOF MS是一种快速、准确且可靠的检测结核分枝杆菌中与利福平耐药相关的rpoB基因突变的方法。其与DNA测序的高度一致性、出色的诊断性能以及识别异质性耐药的能力突出了其作为早期结核病诊断的宝贵工具以及提高化疗方案制定精度的潜力。重要性耐多药结核病(MDR-TB)和利福平耐药结核病(RR-TB)的出现对全球结核病(TB)控制工作构成了重大挑战。利福平(RIF)耐药是耐多药结核病的关键标志物,耐多药结核病需要更复杂、更漫长且成本更高的治疗方案。早期准确检测利福平耐药对于有效控制结核病至关重要。本研究评估了核苷酸MALDI-TOF MS这一创新技术检测rpoB基因中与利福平耐药相关突变的性能。该方法显示出高灵敏度(93.2%)和特异性(98.1%),还具有识别异质性耐药的额外优势,而这是传统方法所缺乏的能力。这些能力对于早期诊断、指导个性化治疗方案以及遏制耐药结核病的传播至关重要。研究结果表明,核苷酸MALDI-TOF MS为检测与利福平耐药相关的rpoB基因突变提供了一种快速、高通量且经济高效的替代方法。